Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019
July 31 2019 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus by selectively targeting peripheral
kappa opioid receptors, today announced that the Company will host
a conference call and live audio webcast on Wednesday, August 7,
2019, at 4:30 p.m. ET to report second quarter 2019 financial
results and provide a corporate update.
To participate in the conference call, please
dial (855) 445-2816 (domestic) or (484) 756-4300 (international)
and refer to conference ID 6576266. A live webcast of the call can
be accessed under “Events and Presentations” in the News &
Investors section of the Company’s website at
www.CaraTherapeutics.com.
An archived webcast recording will be available
on the Cara website beginning approximately two hours after the
call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors (KORs). Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body's peripheral nervous system, as well as
certain immune cells. In both Phase 3 and Phase 2 trials, KORSUVA
Injection has demonstrated statistically significant reductions in
itch intensity and concomitant improvement in quality of life
measures in hemodialysis patients with moderate-to-severe chronic
kidney disease-associated pruritus (CKD-aP). KORSUVA Injection is
currently being investigated in pivotal Phase 3 trials in
hemodialysis patients with CKD-aP. Oral KORSUVA is in Phase 2
trials for the treatment of pruritus in patients with CKD, atopic
dermatitis and primary biliary cholangitis (PBC).
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
MEDIA CONTACT: Annie Starr 6
Degrees 973-415-8838 astarr@6degreespr.com
INVESTOR CONTACT: Jane Urheim
Stern Investor Relations, Inc. 212-362-1200
Jane.Urheim@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2023 to Sep 2024